The role of S100 proteins and their receptor RAGE in pancreatic cancer

Estelle Leclerc; Stefan W Vetter

doi:10.1016/j.bbadis.2015.09.022

The role of S100 proteins and their receptor RAGE in pancreatic cancer

Biochim Biophys Acta. 2015 Dec;1852(12):2706-11. doi: 10.1016/j.bbadis.2015.09.022. Epub 2015 Oct 3.

Authors

Estelle Leclerc¹, Stefan W Vetter²

Affiliations

¹ Department of Pharmaceutical Sciences, North Dakota State University, PO Box 6050, Department 2665, Fargo, ND 58108-6050, USA. Electronic address: Estelle.Leclerc@ndsu.edu.
² Department of Pharmaceutical Sciences, North Dakota State University, PO Box 6050, Department 2665, Fargo, ND 58108-6050, USA.

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease with low survival rates. Current therapeutic treatments have very poor response rates due to the high inherent chemoresistance of the pancreatic-cancer cells. Recent studies have suggested that the receptor for advanced glycation end products (RAGE) and its S100 protein ligands play important roles in the progression of PDAC. We will discuss the potential role of S100 proteins and their receptor, RAGE, in the development and progression of pancreatic cancer.

Keywords: Pancreatic ductal adenocarcinoma; RAGE; S100 proteins.

Publication types

Review

Grants and funding

P30 GM103332/GM/NIGMS NIH HHS/United States